Combination Comprising Ribociclib and Amcenestrant
AssigneeSanofi
InventorsMonsif Bouaboula, Fangxian Sun
Life of this patent
Estimating the term…
Abstract
Herein are provided a combination of ribociclib, or a pharmaceutically acceptable salt thereof, such as ribociclib succinate, and amcenestrant, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.
Claims21
1-17. (canceled)
A combination comprising amcenestrant or a pharmaceutically acceptable salt thereof, and ribociclib or a pharmaceutically acceptable salt thereof.
A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of ribociclib or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising amcenestrant or a pharmaceutically acceptable salt thereof, ribociclib or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
A method of treating cancer in a patient who is being treated with amcenestrant or a pharmaceutically acceptable salt thereof, comprising administering to the patient an effective amount of ribociclib or a pharmaceutically acceptable salt thereof.
A method of treating cancer in a patient on stable treatment with amcenestrant or a pharmaceutically acceptable salt thereof, comprising administering to the patient a therapeutically effective amount of ribociclib or a pharmaceutically acceptable salt thereof.
A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of ribociclib or a pharmaceutically acceptable salt thereof, wherein said patient is also being treated with amcenestrant or a pharmaceutically acceptable salt thereof.
A kit comprising:
- (i) a first pharmaceutical composition comprising amcenestrant or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
- and
- (ii) a second pharmaceutical composition comprising ribociclib or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
- wherein the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments.
The kit of claim 36, wherein the cancer is breast cancer.
Dependencies are inferred from the claim text.